STM 434

Drug Profile

STM 434

Alternative Names: STM-434

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Atara Biotherapeutics
  • Class Antibodies; Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Type-II-B activin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ovarian cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ovarian-cancer in USA (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
  • 13 Jan 2017 Santa Maria Biotherapeutics completes a phase I trial in Solid tumours and Ovarian cancer (Late-stage disease, Combination therapy) in USA (NCT02262455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top